Please note, this slide builds.
Key message: Treatment adverse events, which are reported by the majority of patients with schizophrenia, can impose a significant burden on patients, reducing quality of life and causing long-term distress if not treated.
Background
In an Australian study that combined the findings of two studies of patients with psychosis (the first in 1997–1998 [n=687], the second in 2010 [n=1,211]), 77.4% reported medication adverse events in the previous 4 weeks, 61.0% reported impairment due to medication adverse events, and 29.9% reported moderate/severe impairment due to adverse events.[Morgan et al., 2010]
The ‘Psychosis Screener’ was used for census month screening, and the ‘Diagnostic Interview for Psychosis’ was used for the interview.[Morgan et al., 2010] The proportions reporting medication adverse events and associated impairment were comparable for both survey periods.[Morgan et al., 2010] Questions from the 1997−1998 psychosis survey were included to enable an assessment of change over time.[Morgan et al., 2010]
Reference:
Morgan VA, Waterreus A, Jablensky A, et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012; 46 (8): 735–752.
Other references used on slide:
Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl 1994; 380: 27–32.
Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25 (5): 567–620.